Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald After Ph 2 CADENCE Data Release
Tweet Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $120.00 price target on Merck (NYSE: MRK).The analyst commented, "Merck ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
